
AEVI Genomic Medicine (GNMX) was active in trading today. While the reason for the bump in activity is not immediately evident, it is possibly related to potential developments with the company’s pipeline research, including possible additional investment to keep the company sufficiently funded to complete its current research for one of its products. The company’s stock is down greatly since the beginning of the year due to a failure of a phase 2 study. Here’s a recap.